Evidence map›Paper›PMID 40401515›Full record

ArticleDermatology reports2026

Retrospective multicenter study on severely dysplastic melanocytic nevi: evaluating the need for re-excision and the risk of recurrence or progression.

Cesare Ariasi, Carlo Cota, Cesare Massone, Carmine D'Acunto, Pietro Danese, Maurizio Lombardo, Davide Melandri, Francesca Scarpellini, Rosa Rinaldi, Paola Pasquini and 3 more

Abstract read
In one paragraph

Article in Dermatology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Cesare AriasiDepartment of Dermatology, University of Brescia.
Carlo CotaUnit of Dermatopathology, San Gallicano Dermatological Institute, Rome.
Cesare MassoneDermatology Unit, Galliera Hospital, Genoa.
Carmine D'AcuntoDermatology Unit and Burn Center AUSL Romagna, Cesena Hospital.ORCID 0000-0001-8974-8186
Pietro DaneseDermatology Unit, Carlo Poma Hospital, ASST Mantova.
Maurizio LombardoMelanoma Skin Centre, Department of Medicine and Surgery, Circolo Hospital and Macchi Foundation, ASST dei Sette Laghi, Varese.ORCID 0000-0002-9502-5133
Davide MelandriDermatology Unit and Burn Center AUSL Romagna, Cesena Hospital.
Francesca ScarpelliniDepartment of Pathology, AUSL Romagna, Cesena Hospital.
Rosa RinaldiPathology Unit, Carlo Poma Hospital, ASST Mantova.
Paola PasquiniUnit of Dermatopathology, San Gallicano Dermatological Institute, Rome.
Paolo IncardonaDepartment of Pathology, ASST Spedali Civili, Brescia.ORCID 0000-0001-8828-6565
Piergiacomo Calzavara-PintonDepartment of Dermatology, University of Brescia.ORCID 0000-0002-0935-7204
Paola MonariDepartment of Dermatology, University of Brescia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severely dysplastic melanocytic nevi (SMD) are histologically challenging lesions with no consensus on optimal management. While complete excision is widely recommended, the necessity of additional re-excision remains debated. This retrospective, multicenter observational cohort study evaluated the risk of recurrence and disease progression in patients with SMD by comparing those who underwent a single complete excision to those who underwent a secondary widening procedure with 5 mm margins. A total of 226 patients (230 SMD lesions) were included, with diagnoses based on the 2018 World Health Organization (WHO) criteria. Among them, 13.5% underwent re-excision despite clear margins, while 86.5% were followed clinically. Over a minimum 5-year follow-up period, no patient in either group experienced recurrence at the excision site or progression to melanoma. These findings suggest that complete excision with clear margins is sufficient for managing SMD, with no added benefit from routine re-excision. Avoiding unnecessary surgical procedures could reduce patient anxiety, healthcare costs, and surgical morbidity. Given the lack of standardized guidelines, further prospective studies are needed to refine clinical decision-making for SMD management.

Indexed as

dysplastic nevusmelanoma riskSeverely dysplastic melanocytic nevi

Identifiers

PMID40401515
PMCPMC13003388

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.